Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#How Has The Liraglutide And Semaglutide Market Size Shifted, And What Is the Outlook Through 2034?

There has been a quick expansion of the liraglutide and semaglutide market in the past few years. The market is projected to increase from a value of $15.19 billion in 2024 to $16.98 billion in 2025, indicating a compound annual growth rate (CAGR) of 11.8%. Factors such as the rising cases of diabetes, an upward trend in diseases related to obesity, increasing clinical trials, enhanced funding for diabetes research and development, and higher need for easy treatment alternatives contributed to the growth during the historic period.

How Much Will the Liraglutide And Semaglutide Market Be Worth in 2029?

It is predicted that the liraglutide and semaglutide market will experience a substantial growth rate in the upcoming years. The market is estimated to expand to a whopping $26.24 billion in 2029, with a compound annual growth rate (CAGR) of 11.5%. The growth projected in this period can be linked to factors such as the increasing use of GLP-1 receptor agonists, a surge in healthcare spending, enhanced product ranges of pharmaceutical enterprises, growing disposable incomes, and an elderly population at greater risk of diabetes. Significant trends for the forecast period encompass the introduction of digital health platforms, the application of individualized dosing approaches, progress in drug delivery technology, the creation of biosimilar versions, and the employment of artificial intelligence in making treatment decisions.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=18400&type=smp

Which is the Largest Company in the Liraglutide And Semaglutide Market?

Major companies operating in the liraglutide and semaglutide market are Pfizer Inc., Merck & Co. Inc., Bristol-Myers Squibb, AstraZeneca, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Otsuka Holdings Co. Ltd., Sun Pharmaceutical Industries Ltd., Sumitomo Pharma Co. Ltd., Shionogi & Co. Ltd., Cadila Pharmaceuticals, Kyowa Kirin Co. Ltd., Dr. Reddy’s Laboratories Ltd., Biocon, Glenmark Pharmaceuticals Ltd., Bachem, Zealand Pharma, Shenzhen JYMed Technology Co. Ltd., Incepta Pharmaceuticals Ltd.

What Are the Main Market Drivers in the Liraglutide And Semaglutide Industry?

Anticipations for the growth of the liraglutide and semaglutide markets are largely driven by the escalating prevalence of diabetes. Diabetes is a persistent medical condition typified by high blood sugar levels resulting from either insulin resistance or inadequate insulin production in the body. The increasing number of individuals affected by this condition can be attributed to factors like sedentary lifestyles, improper dietary practices, and genetic factors. Liraglutide and semaglutide play a crucial role in diabetes treatment by providing efficient management of blood sugar levels and lessening the chances of other related health complications. For instance, the National Health Service, a government department based in the UK, reported in June 2024, that the NHS identified more than half a million (549,000) new individuals in England who were at risk of developing type 2 diabetes in 2023. This discovery brought the total registered cases of non-diabetic hyperglycemia, also known as pre-diabetes, to 3,615,330 with a GP, reflecting a significant upward shift from 3,065,825 in 2022 – a nearly 20% increase. Hence, the growth of the liraglutide and semaglutide markets can be predominantly attributed to the rising incidence of diabetes.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=18400&type=smp

How Is the Liraglutide And Semaglutide Market Segments Structured?

The liraglutide and semaglutide market covered in this report is segmented –

1) By Type: Pills, Liquid

2) By Administration: Parenteral, Oral

3) By Application: Type 2 Diabetes Mellitus, Obesity, Other Applications

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Pills: Oral Tablets (Liraglutide, Semaglutide), Extended-Release Oral Formulations

2) By Liquid: Injectable Solutions (Liraglutide, Semaglutide), Pre-Filled Syringes, Vials For Injection

What Strategic Trends Are Transforming the Liraglutide And Semaglutide Market?

Leading businesses in the liraglutide and semaglutide markets are focusing on the creation of anti-diabetic biosimilar medicines to boost glucose management and lower cardiovascular threats in diabetic individuals. The biosimilars being developed for diabetes are considered affordable and nearly identical to original diabetes biologic drugs, intended to provide the same patient benefits. For example, in January 2024, Glenmark Pharmaceuticals Ltd, which is based in India, introduced a biosimilar of the widely used anti-diabetic medication, Liraglutide, marking its first launch in India. This biosimilar of Liraglutide aims to enhance glycemic control in adults diagnosed with type 2 diabetes mellitus. The introduction of this medication is set to greatly lower daily treatment expenses, thus widening its availability to patients countrywide. The cost of a regular 1.2 mg daily dose stands at roughly INR 100, enabling a reduction in treatment costs by nearly 70% and necessitating a prescription for its purchase.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/liraglutide-and-semaglutide-global-market-report

Which Global Regions Offer the Highest Growth in the Liraglutide And Semaglutide Market?

North America was the largest region in the liraglutide and semaglutide market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the liraglutide and semaglutide market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=18400

This Report Delivers Insight On:

1. How big is the liraglutide and semaglutide market, and how is it changing globally?

2. Who are the major companies in the liraglutide and semaglutide market, and how are they performing?

3. What are the key opportunities and risks in the liraglutide and semaglutide market right now?

4. Which products or customer segments are growing the most in the liraglutide and semaglutide market?

5. What factors are helping or slowing down the growth of the liraglutide and semaglutide market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model